Abstract:Objective:To investigate the value of postoperative radiotherapy in patients with cT 1-2N 1M 0 breast cancer after neoadjuvant chemotherapy and modified radical mastectomy which postoperative pathology showed that the number of axillary lymph node metastases was 0-3. Methods:One hundred and twenty-eight patients diagnosed with cT 1-2N 1M 0 breast cancer admitted to our hospital from January 1, 2000 to December 31, 2014 were retrospectively reviewed. All patients underwent neoadjuvant chemotherapy and modified radical mastectomy. The number of postoperative axillary lymph node metastases was 0-3. According to whether there was postoperative radiotherapy or not, the whole group of patients was divided into radiotherapy group ( n=87) and non-radiotherapy group ( n=41). In the two groups after operation, there were 43 and 11 patients with 1-3 axillary lymph node metastases (ypN 1), while there were 44 and 30 patients without axillary lymph node metastases (ypN 0) respectively. The 5-year locoregional recurrence-free survival (LRFS) rate, disease-free survival (DFS) rate and overall survival (OS) rate were calculated by Kaplan-Meier method, and the differences were compared by log-rank test. Univariate analysis was performed to analyze the effects of clinical features and treatment on prognosis. Results:The 5-year LRFS rate, DFS rate and OS rate of 128 patients were 91.4%, 82.8% and 93.0% respectively. The 5-year LRFS rates of the patients in the radiotherapy group and the non-radiotherapy group were 94.3% and 85.4% respectively, and the difference was not statistically significant ( χ2=3.055, P=0.080). As well as the 5-year DFS rates were 89.7% and 68.3% respectively, and the difference was statistically significant ( χ2=9.312, P=0.005). The 5-year OS rates were 94.3% and 90.2% respectively, and the difference was not statistically significant ( χ2=0.810, P=0.368). In the subgroup analysis, the 5-year LRFS rates of the patients who had achieved ypN 1 in the radiotherapy group and the non-radiotherapy group were 93.0% and 72.7%, and the 5-year DFS rates were 88.4% and 63.6%, with statistically significant differences ( χ2=4.248, P=0.039; χ2=4.525, P=0.033). The 5-year OS rates were 90.7% and 81.8% respectively, and the difference was not statistically significant ( χ2=0.713, P=0.399). The 5-year LRFS rates of the patients who had achieved ypN 0 in the radiotherapy group and the non-radiotherapy group were 95.5% and 90.0% respectively, with no statistically significant difference ( χ2=0.872, P=0.350). The 5-year DFS rates were 90.9% and 70.0% respectively, with statistically significant difference ( χ2=5.439, P=0.019). The 5-year OS rates were 97.7% and 93.3% respectively, with no statistically significant difference ( χ2=0.876, P=0.349). The univariate analysis indicated that age ( χ2=11.709, P=0.001) and blood vessel invasion ( χ2=7.608, P=0.006) were significant influencing factors for 5-year LRFS rate. Postoperative radiotherapy ( χ2=9.312, P=0.002) was a prognostic factor for 5-year DFS rate. Age ( χ2=6.093, P=0.014) and hormone receptor status ( χ2=3.974, P=0.046) were prognostic factors for OS. Conclusion:For the cT 1-2N 1M 0 breast cancer patients with 1-3 positive axillary lymph nodes after neoadjuvant chemotherapy, postmastectomy radiotherapy has local control benefit, and it can improve DFS. However, the benefit of postoperative radiotherapy needs to be further investigated in patients with pathological negative axillary lymph nodes after neoadjuvant chemotherapy.

Radiotherapeutic Management of Regional Lymph Nodes Recurrence Following Mastectomy

Value of Postmasteetomy Radiotherapy in T_2 Breast Cancer Patients with 1-3 Positive Axillary Lymph Nodes

Radiotherapy for and Prognosis of Breast Cancer Patients with Local-Regional Recurrence after Mastectomy

Radiotherapy and prognostic analysis of recurrent breast cancer

Role of radiotherapy and prognostic factors in breast cancer patients at high-risk of recurrence trea-ted with modified radical mastectomy and chemotherapy

P268 Frequency and Anatomical Characteristics of Involved Regional Lymph Nodes in Recurrent and Advanced Breast Cancer

The Role of Postmastectomy Radiotherapy in Breast Cancer Patients with T1-T2 and One to Three Positive Axillary Nodes

Radiotherapy following modified radical mastectomy significantly improves locoregional control in patients with Rec-/HER-2+ locally advanced breast cancer

Positive metastasis axillary lymph nodes after radical mastectomy for breast cancer as an indication of postoperative radiotherapy

Radiotherapy for 64 Cases with Postoperative Chestwall Local Recurrence of Breast Cancer

Locoregional Recurrence Analysis in Young Women (≤35 Years) Receiving Mastectomy with Operable Breast Cancer

Factors influencing local control after radiotherapy for isolated local-regional recurrence after mastectomy

Impact of Clinical-pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Can We Omit Adjuvant Radiotherapy?

Postmastectomy locoregional recurrence and survival in early stage breast cancer patients with one to three axillary lymph node metastases]

Indications for Postmastectomy Radiotherapy in Breast Cancer Patients with 1 -3 Positive Axillary Nodes

The Locoregional Recurrence Risk and Failure Pattern for Breast Cancer Patients with 1 to 3 Positive Nodes and Treated with Mastectomy and Contemporary Systemic Therapy

Survival Analysis of Postmastectomy Radiotherapy for Breast Cancer Staged in Ct 1-2N 1M 0 after Neoadjuvant Chemotherapy with 0-3 Metastatic Lymph Nodes

Prognosis and Prophylactic Regional Nodal Irradiation in Breast Cancer Patients With the First Isolated Chest Wall Recurrence After Mastectomy

Failure patterns of locoregional recurrence in women with T1-2N1 breast cancer after modified radical mastectomy

The Role of Postmastectomy Radiotherapy in Different Molecular Subtypes of Breast Cancer Patients with T 1 - T 2 and One to Three Positive Axillary Nodes

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?